

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Burkhard GÖKE *et al.*

Group Art Unit: 1653

Appln. No.: 09/719,410

Examiner: Abdel A. MOHAMED

Filed: December 12, 2000

Atty. Docket: 18528.543 / 0206-UTL-9

For: **Glucagon-Like Peptide 1 Improves
B-Cell Response to Glucose in Subjects
with Impaired Glucose Tolerance**

Confirmation No.: 8826

INFORMATION DISCLOSURE STATEMENT

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the documents listed on the attached Form PTO-1449. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

CERTIFICATION AND/OR FEE

Because this Information Disclosure Statement is being submitted after issuance of the first action on the merits of the above-captioned application, a fee of \$180.00 is due pursuant to 37 C.F.R. § 1.17(p). Applicants request that this fee be charged to Deposit Account No. 50-2387 referencing docket number 18528.543.

Respectfully submitted,

Rachel L. Adams


David R. Marsh (Reg. No. 41,408)
Rachel L. Adams (Reg. No. 54,660)

Date: May 27, 2005

ARNOLD & PORTER LLP
555 Twelfth Street, N.W.
Washington, D.C. 20004-1206
(202) 942-5000 telephone
(202) 942-5999 facsimile

05/31/2005 SDENB081 00000082 502387 09719410
03.FC:1806 180.00 DA

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT



ATTY. DOCKET NO.

18528.543 / 0206-UTL-9

APPLICATION NO.

09/719,410

APPLICANTS

Burkhard GÖKE *et al.*

FILING DATE

December 12, 2000

GROUP

1653

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AF1						Yes No
	AG1						Yes No
	AH1						Yes No
	AI1						Yes No
	AJ1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AK1	Byrne <i>et al.</i> , "Glucagon-Like Peptide-1 Improves the Ability of the β -Cell to Sense and Respond to Glucose in Subjects with Impaired Glucose Tolerance", <u>Diabetes</u> , Vol. 46, Supplement (1), page 33A, Abstract 0127 (1997)
	AL1	Byrne <i>et al.</i> , "GLP-1 Improves First Phase Insulin Secretion without Altering Insulin Sensitivity in Subjects with Impaired Glucose Tolerance", <u>Diabetes</u> , Vol. 47, Supplement (1), page A192, Abstract 0744 (1998)
	AM1	Byrne & Göke, "Human Studies with Glucagon-like-peptide-1: Potential of the Gut Hormone for Clinical Use", <u>Diabetic Medicine</u> , Vol. 13, pp. 854-860 (1996)
	AN1	Wang <i>et al.</i> , "Glucagon-like Peptide-1 Can Reverse the Age-related Decline in Glucose Tolerance in Rats", <u>The Journal of Clinical Investigation</u> , Vol. 99, No. 22, pp. 2883-2889 (1997)
	AO1	
	AP1	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.